Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction

Uwe Kühl; Matthias Pauschinger; Peter Schwimmbeck; Bettina Seeberg; Conny Lober; Michel Noutsias; Wolfgang Poller; Heinz‐Peter Schultheiß

doi:10.1161/01.cir.0000072766.67150.51

June 4, 2003CirculationOpen Access

Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does interferon-beta treatment eliminate viral genomes and improve LV function in patients with myocardial enteroviral or adenoviral persistence and LV dysfunction?

Key Points

To assess the safety and efficacy of a 6-month interferon-beta regimen in patients with persistent myocardial viral infections and left ventricular dysfunction.
Administered a 6-month course of interferon-beta (IFN-β) therapy to patients with persistent enteroviral or adenoviral genomes in the myocardium and left ventricular dysfunction (N=22).
Evaluated treatment safety, elimination of myocardial viral genomes, and changes in left ventricular performance.
Interferon-beta therapy was safe and eliminated viral genomes in 100% of treated individuals (22 of 22 patients).
Left ventricular function improved in 68.2% of treated individuals (15 of 22 patients) following the 6-month regimen.

Structured PICO

Does interferon-beta treatment eliminate viral genomes and improve LV function in patients with myocardial enteroviral or adenoviral persistence and LV dysfunction?

P

Population

22 patients with myocardial enteroviral or adenoviral persistence and left ventricular (LV) dysfunction

I

Intervention

Interferon-beta (IFN-beta) treatment for 6 months

O

Outcome

Elimination of viral genomes and improvement in LV functionsurrogate

A 6-month course of interferon-beta safely eliminated viral genomes and improved left ventricular function in patients with viral persistence and LV dysfunction.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Should not change practice; hypothesis-generating for RCTs of IFN-beta in viral cardiomyopathy.

Abstract

A 6 months, IFN-beta treatment was safe in patients with myocardial enteroviral or adenoviral persistence and LV dysfunction and resulted in elimination of viral genomes (22 of 22 patients) and improved LV function (15 of 22 patients).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kühl et al. (2003) studied this question.

synapsesocial.com/papers/69effb364f6a06657c21e377 https://doi.org/10.1161/01.cir.0000072766.67150.51

View Full Paper

Ask AI

Bookmark

Share

Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading